Table 4.
Effect of Tamarindus indica L. tablets on serum lipid profile in CCl4 induced hepatotoxicity in Sprague Dawley rats.
| Group | TG (mg/dL) |
CHOL (mg/dL) |
HDL-c (mg/dL) |
LDL-c (mg/dL) |
VLDL-c (mg/dL) |
|---|---|---|---|---|---|
| I | 48.41 ± 2.26c | 94.91 ± 3.16c | 49.59 ± 1.83a | 35.64 ± 1.75b | 9.68 ± 0.95b |
| II | 120.57 ± 6.90a | 151.00 ± 3.43a | 25.98 ± 2.06c | 100.91 ± 5.43a | 24.11 ± 1.32a |
| III | 56.88 ± 2.94b | 96.56 ± 2.78b | 51.24 ± 1.16a | 33.94 ± 2.02b | 11.38 ± 1.59b |
| IV | 52.32 ± 3.39c | 92.58 ± 2.99c | 46.41 ± 1.40b | 35.71 ± 0.98b | 10.46 ± 0.98b |
| V | 50.83 ± 2.04c | 90.59 ± 2.71c | 48.29 ± 1.33b | 32.13 ± 1.95c | 10.17 ± 0.91b |
TG: triglycerides, CHOL: cholesterol, HDL: high-density lipoproteins, LDL: low-density lipoproteins, and VLDL: very low-density lipoproteins (-c, bounded to cholesterol).
I: normal group; II: CCl4 induced hepatotoxicity group; III: Silymarin treated group; IV and V: Tamarindus indica L. tablets treated groups at doses 100 mg/kg and 200 mg/kg, respectively.
Different letters on columns indicate significant statistical differences in Tukey HSD test.
Data are expressed as mean ± SD; n = 7.